Novo and Lilly gain on signs weight-loss pills could expand the market

Early data on weight-loss pills is lifting Novo Nordisk and Eli Lilly shares as investors bet easier-to-take drugs could expand the market to millions more patients. The development may also help offset pricing pressure in the obesity drug segment. The news is positive for both companies, but it is still early-stage and more a sentiment driver than a confirmed fundamental inflection.

Analysis

Early data on weight-loss pills is lifting Novo Nordisk and Eli Lilly shares as investors bet easier-to-take drugs could expand the market to millions more patients. The development may also help offset pricing pressure in the obesity drug segment. The news is positive for both companies, but it is still early-stage and more a sentiment driver than a confirmed fundamental inflection.